IMO, MediPharm has it's financial act together. They could have filed sooner. Therefore it might be reasonable to assume, all was not great during the Covid-19 onset. It might also be reasonable to assume to counteract the negative, they want to include in the report more of the current items that look great on the surface.
And perhaps the big volume is in anticipation of a good Q despite the negatives that might be contained in it.
I sure would like to see it acting more like Valens.
MediPharm Labs Corp., will file its first quarter 2020 financial statements and management's discussion and analysis for the three-month period ended March 31, 2020 ("First Quarter Financial Information") on or before June 29, 2020.
In response to the coronavirus pandemic, Canadian securities regulatory authorities have granted a blanket exemption allowing issuers an additional 45 days to complete their regulatory filings. Normally, MediPharm Labs would report first quarter results on or before May 15, 2020 but given the unprecedented disruptions caused by COVID-19, the Company is relying on this exemptive relief from the filing timelines for its First Quarter Financial Information required by sections 4.4 and 5.1(2) of National Instrument 51-102. In accordance with the blanket exemption, the Company is not permitted to file any preliminary or final prospectus while it is relying on this filing deadline relief.
News 
Market Data 
Discover 
